Injectable Poloxamer Hydrogel Formulations for Intratympanic Delivery of Dexamethasone

J Korean Med Sci. 2023 May 1;38(17):e135. doi: 10.3346/jkms.2023.38.e135.

Abstract

Background: In this study, we prepared and evaluated an injectable poloxamer (P407) hydrogel formulation for intratympanic (IT) delivery of dexamethasone (DEX).

Methods: DEX-loaded P407 hydrogels were characterized in terms of thermogelation, drug loading capacities, particle size, and drug release. The in vivo toxicity and drug absorption of the DEX-loaded P407 formulation after IT injection were evaluated using an animal model by performing histopathological analysis and drug concentration measurements.

Results: The P407 hydrogel effectively solubilized hydrophobic DEX and demonstrated a sustained release compared to the hydrophilic DEX formulation. The in vivo study showed that the hydrogel formulation delivered considerable drug concentrations to the inner ear and displayed a favorable safety profile without apparent cytotoxicity or inflammation.

Conclusion: P407 hydrogel can be useful as an injectable inner ear delivery formulation for hydrophobic drugs due to their biocompatibility, drug-solubilizing capacity, thermogelation, and controlled release.

Keywords: Dexamethasone; Injectable Hydrogel; Inner Ear Delivery; Intratympanic Injection; Poloxamer.

MeSH terms

  • Animals
  • Dexamethasone
  • Drug Liberation
  • Hydrogels* / chemistry
  • Poloxamer* / chemistry

Substances

  • Poloxamer
  • Hydrogels
  • Dexamethasone